Dialysability of Gadoteric Acid in Patients With End-Stage Renal Disease Undergoing Hemodialysis
Authors:
- Ronald DaelemansRDRonald Daelemans
- Sofie MesensSMSofie Mesens
- 1 August 2014
- journal article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 49 (8) , 505-508
Abstract
This study was designed to evaluate the dialysability of gadoteric acid in patients with end-stage renal disease (ESRD) requiring hemodialysis. Gadoteric acid is used for magnetic resonance imaging. It is cleared from the blood exclusively by glomerular filtration. In an attempt to decrease the occurrence of nephrogenic systemic fibrosis, hemodialysis has been advocated immediately after injection of gadolinium-based contrast agents in patients with ESRD. Ten patients with ESRD underwent 3 consecutive 4-hour hemodialysis sessions after a single intravenous injection (0.1 mmol/kg) of gadoteric acid. Blood samples were drawn from the vascular access just before and immediately after the end of each 4-hour session. Additional sampling was performed during session 1. Gadoteric acid was efficiently eliminated, with mean (95% confidence interval) clearance values (mL/min) of 224.6 (216.0-233.9) at 0.5 hours and 225.9 (215.6-237.2) at 1.5 hours during session 1. The gadolinium concentration decrease after a 4-hour hemodialysis (vs the corresponding predialysis values) was 97% after session 1. The decrease in gadolinium concentration after session 3 was 99.7% compared with the predialysis concentration of session 1. These percentages are similar to those reported after hemodialysis for other gadolinium-based contrast agents. No adverse effects related to gadoteric acid were reported. Although no unconfounded case of nephrogenic systemic fibrosis has been reported so far after injection of gadoteric acid, hemodialysis can be efficiently used to remove this molecule in patients with ESRD already undergoing long-term hemodialysis.Keywords
This publication has 20 references indexed in Scilit:
- Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast AgentsInvestigative Radiology, 2014
- Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)European Radiology, 2012
- Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelinesEuropean Radiology, 2012
- Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast AgentsAdvances in Chronic Kidney Disease, 2011
- Dialyzability of gadodiamide in hemodialysis patientsRadiation Medicine, 2006
- Using Highly Concentrated Gadobutrol as an MR Contrast Agent in Patients Also Requiring HemodialysisAmerican Journal of Roentgenology, 2002
- Safety of gadolinium contrast agent in hemodialysis patientsActa Radiologica, 2001
- Permeability of Gadolinium-DTPA Through Two Types of Hemodialysis MembraneInvestigative Radiology, 1998
- Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysisAcademic Radiology, 1998
- Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failureEuropean Radiology, 1992